Surveillance of vaccine breakthrough cases following MeNZB vaccination

New Zealand Medical Journal

Volumn 121, Issue 1272, 2008, Pages

  McNicholas, Anne ^a   Galloway, Yvonne ^a   Martin, Diana ^b   Sexton, Kerry ^a   O'Hallahan, Jane ^a  

^a MINISTRY OF HEALTH   (New Zealand)

^b INSTITUTE OF ENVIRONMENTAL SCIENCE AND RESEARCH   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

MENINGOCOCCUS VACCINE;

ADOLESCENT; ADULT; ARTICLE; BACTERIAL STRAIN; CHILD; CONTROLLED STUDY; EPIDEMIC; HUMAN; IMMUNIZATION; IMMUNOCOMPETENCE; INCIDENCE; INFANT; INFECTION RATE; INFECTION RISK; LABORATORY TEST; MAJOR CLINICAL STUDY; MENINGOCOCCOSIS; NEISSERIA MENINGITIDIS; QUESTIONNAIRE; RISK FACTOR; VACCINATION; EPIDEMIC MENINGITIS; ETHNIC GROUP; HEALTH SURVEY; IMMUNOLOGY; METHODOLOGY; NEW ZEALAND; PRESCHOOL CHILD; REGISTER;

ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; DISEASE OUTBREAKS; ETHNIC GROUPS; HUMANS; IMMUNIZATION SCHEDULE; INFANT; MENINGITIS, MENINGOCOCCAL; MENINGOCOCCAL VACCINES; NEW ZEALAND; POPULATION SURVEILLANCE; REGISTRIES;

EID: 42949138838     PISSN: None     EISSN: 11758716     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Wong S, Lennon D, Jackson C, et al. New Zealand epidemic strain meningococcal B outer membrane vesicle vaccine in children aged 16-24 months. Pediatr Infect Dis J. 2007;26(4):345-50.
2. Oster P, O'Hallahan J, Aaberge I, et al. Immunogenicity and safety of a strain-specific MenB OMV vaccine delivered to under 5-year olds in New Zealand. Vaccine. 2007;25:3075-9.
3. O'Hallahan J, Lennon D, Oster P, et al. From secondary prevention to primary prevention: A unique strategy that gives hope to a country ravaged by meningococcal disease. Vaccine. 2005;23:2197-201.
4. McNicholas A, Galloway Y, Stehr-Green P, et al. Post-marketing safety monitoring of a new group B meningococcal vaccine in New Zealand, 2004-2006. Hum Vaccin. 2007;3(5):195-204.
5. Holst J, Feiring B, Naess L, et al. The concept of "tailor-made", protein-based, outer membrane vesicle vaccines against meningococcal disease. Vaccine. 2005;23:2202-5.
6. Ramsay ME, Andrews N, Kaczmarski EB, Miller E. Efficacy of meningococcal serogroup C conjugate vaccine in teenagers and toddlers in England. Lancet. 2001;357:195-6.
7. American Academy of Pediatrics Committee on Infectious Diseases. Policy Statement. Prevention and control of meningococcal disease: recommendations for use of meningococcal vaccines in pediatric patients. Pediatrics. 2005;116(2):496-505.
8. Martin D, McCallum L, Glennie A, et al. Validation of the serum bactericidal assay for measurement of functional antibodies against group B meningococci associated with vaccine trials. Vaccine. 2005;23:2218-21.
9. Orenstein WA, Bernier RH, Hinman AR. Assessing vaccine efficacy in the field: Further observations. Epidemiol Rev. 1988;10:212-41.
10. Sierra GVG, Campa HC, Varcacel NM, et al. Vaccine against group B Neisseria meningitidis: Protection trial and mass vaccination results in Cuba. NIPH Ann. 1991;14(2):195-210.
11. Holst J, Feiring B, Fuglesang JE, et al. Serum bactericidal activity correlates with the vaccine efficacy of outer membrane vesicle vaccines against Neisseria meningitidis serogroup B disease. Vaccine. 2003;21:734-37.
12. Kelly C, Arnold R, Galloway Y, O'Hallahan J. A prospective study of the effectiveness of the New Zealand meningococcal B vaccine. Am J Epidemiol. 2007;166:817-23.
13. CBG. Audit of MeNZB™ data in the National Immunisation Register. Round 2. Accuracy and completeness up to March 2005. Prepared for the Ministry of Health. CBG Health Research Limited. May 2005.
14. Martin D R, Ruijne N, McCallum L et al. The VR2 epitope on the PorA P1.7-2,4 protein is the major target for the immune response elicited by the strain-specific group B meningococcal vaccine MeNZB. Clin Vaccine Immunol. 2006;13:487-91.
15. Sjoholm AG, Truedsson L, Jensenius JC. Complement pathways and meningococcal disease. In: Pollard AJ & Maiden MCJ, eds. Methods in Molecular Medicine. Meningococcal disease. Methods and protocols. Vol. 67. Totowa, New Jersey: Humana Press Inc, 2001:529-47.
16. Schneider MC, Exley RM, Ram S. et al. Interactions between Neisseria meningitidis and the complement system. Trends Microbiol. 2007;15(5):233-40.